US Patent

US9802932 — Solid forms of a compound modulating kinases

Composition of Matter · Assigned to Plexxikon Inc · Expires 2036-05-05 · 10y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid forms of a compound called Pexidartinib hydrochloride, which modulates kinases.

USPTO Abstract

Also provided are methods of using the solid forms.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US9802932
Jurisdiction: US
Classification: Composition of Matter
Expires: 2036-05-05
Drug substance claim: Yes
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.